Anti-Human CD40 (Clone CPTC-CD40-4) — Purified No Carrier Protein
Anti-Human CD40 (Clone CPTC-CD40-4) — Purified No Carrier Protein
Product No.: LTCC236
- -
- -
Clone FSAI138R Target CD40 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Tumor necrosis factor receptor superfamily member 5 (TNFRSF5), B-cell surface antigen CD40, Bp50, CD40L receptor, CDw40 Isotype Mouse IgG2b κ Applications WB , immuno-MRM |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Human CD40 peptide sequence SCSPGFGVK Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. State of Matter Liquid Product Preparation Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco Immuno-MRM, WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity FSAI138R-7G6 activity is directed against CD40 peptide sequence SCSPGFGVK. CPTC Clone ID CPTC-CD40-4 Background CD40 (also known as TNFRSF5) and CD40L (TNFSF5) are a receptor ligand pair belonging to
the tumor necrosis factor receptor/TNF superfamily that functions in immune regulation1. CD40 acts as a co-stimulatory receptor that, when interacting with its ligand CD40L on activated T cells, promotes activation, survival, production of pro-inflammatory cytokines and chemokines in dendritic cells, macrophages, and B cells, and enhances tumor antigen presentation1,2. This in turn can further activate tumor-infiltrating lymphocytes2. CD40 is a target of immunotherapy to limit the activity of antigen presenting cells and T cells in cancer, autoimmune disease, and inflammatory disease1,2. FSAI138R-7G6 was generated in mouse for use in immuno-MRM assays using a synthetic peptide derived from human CD40 that is carbamidomethylated at the cysteine, SC[cam]SPGFGVK3. FSAI138R-7G6 detects CD40 by Western blotting in HeLa, A549, MCF7, and H226 cell lysates, with some bands running higher than expected due to glycosylation4. FSAI138R-7G6 does not detect recombinant CD40 by Western blotting. FSAI138R-7G6 also does not detect CD40 by reverse phase protein array. Antigen Distribution CD40 is expressed by B cells and in primary carcinomas. Ligand/Receptor CD40L (CD154) NCBI Gene Bank ID UniProt.org Research Area Immuno-Oncology . Autoimmunity . Cancer Research References & Citations1 Locksley RM, Killeen N, Lenardo MJ. Cell. F104(4):487-501. 2001. 2 Croft M, Salek-Ardakani S, Ware CF. Nat Rev Drug Discov. 23(12):939-961. 2024. 3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021. 4 https://antibodies.cancer.gov/detail/CPTC-CD40-4 Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LTCC236 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
